Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PR-104 |
| Synonyms | |
| Therapy Description |
PR-104 is a hypoxia-activated prodrug that causes DNA cross-linking within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 17606726, PMID: 26116659). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PR-104 | PR104|PR 104 | PR-104 is a hypoxia-activated prodrug that causes DNA cross-linking within hypoxic regions of tumors, potentially providing antineoplastic activity (PMID: 17606726, PMID: 26116659). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 dec exp | triple-receptor negative breast cancer | sensitive | PR-104 | Preclinical | Actionable | In a preclinical study, knockdown of PALB2 enhanced growth inhibition by PR-104 in triple-negative breast cancer cell lines in culture (PMID: 25193512). | 25193512 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|